# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:LGVN) with a Buy and maintains $12 price ta...
Longeveron (NASDAQ:LGVN) reported quarterly losses of $(1.61) per share which beat the analyst consensus estimate of $(2.00) by...
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11975068
https://t.co/L1bepDtcf3
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Longeveron (NASDAQ:LGVN) with a Buy, adjusts target to $12 from...
Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developin...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The D...